Celgene Yields The Most

Summary

Celgene continues to boost EPS estimates while the stock trades at multi-year lows.

Revlimid faces patent questions that aren't likely to disappear, making the large pipeline important in reducing the risk.

The stock offers the highest net payout yield in the market with a yield of nearly 15%.

When a biopharma faces an end-of-patent scenario with a key drug, the stock will typically trade at what appears irrational levels. Such is the case with Celgene (CELG) now trading not far off multi-year lows despite the reality that a key drug in Revlimid actually has years before facing that pain. The company is using that fact to generate the highest yield of a stock in the large-cap sector.

Revlimid logoImage Source: Celgene website

READ FULL ARTICLE HERE